Fundraising FoxRidgeback Capital
Venture capitalNew York · Seed–Late Stage · 1 people tracked
Also known as MANDALAY FINANCIAL, L.L.C.
Find your way into Ridgeback Capital
Each arrow is one introduction. Sign up to fill in the first one.
Ask Sumant Datta to introduce you to Wayne Holman
You →Sumant · together at Ridgeback Capital →Wayne
Sign up to find every way you can get introduced to Ridgeback Capital
- Your email: who you already know at Ridgeback Capital, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Ridgeback Capital team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Ridgeback Capital invests in private and public healthcare companies dedicated to developing life-saving and life-changing therapies. The firm targets ideas, technologies and companies that will make a difference, believing that behind every advance is a team of people who made it happen. Because healthcare progress often takes many years, the firm emphasizes patient capital drawn from a long-term private investment pool separate from its securities trading platform, giving it flexibility to support innovators and fund important change over extended time horizons.
Source: firm website, verified Sep 27, 2026.
Team · 1 people
from the firm's websiteWhat they invest in
from 51 of 111 portfolio companiesBiotech ×46Healthtech ×33Medical Devices ×17Digital Health ×7AI & Machine Learning ×6Deep Tech ×6Consumer ×2Enterprise Software ×2
HQs:United States×35United Kingdom×2France×1Netherlands×1
Who they back
founder profiles across 24 portfolio companiesFounding team size:solo founder×92 founders×83 founders×34+ founders×4
Where their founders studiedfrom 18 founders with education data
Columbia University ×2Harvard Business School ×2Stanford University ×2The Johns Hopkins University ×2The Johns Hopkins University School of Medicine ×2University of California, Berkeley ×2University of California, San Francisco ×2
What their founders studiedfrom 17 founders with field-of-study data
Life Sciences ×9Engineering ×3Chemistry ×2Mathematics & Statistics ×2Physics ×2
Where their founders worked beforefrom 20 founders with career history
Menlo Ventures ×2
Investments · 111 tracked
founders shown can be your intro pathBy year:2024 · 22018 · 12016 · 22015 · 22014 · 42012 · 112 dated
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Executive Officer, Director)inDavid Schaffer(Director)inTheresa Janke(Executive Officer)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityChiesi VenturesPappas CapitalPfizer Venture Investments+7 more
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
BiotechHealthtechMedical DevicesAbingdon, Oxfordshire, US
James Noble(Chief Executive Officer)Adrian Rawcliffe(Chief Executive Officer and Director)inGavin Wood(Chief Financial Officer)inWilliam Bertrand(Chief Operating Officer)inJohn Lunger(Chief Patient Supply Officer)inElliot Norry(Chief Medical Officer)in
Co-investorsAvoro Capital AdvisorsEight Roads VenturesF-Prime CapitalForesite CapitalNew Enterprise Associates (NEA)Avoro Ventures
Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis.
AI & Machine LearningBiotechHealthtechMedical DevicesThousand Oaks, US
William K. Bowes(Founder)George B. Rathmann(First CEO)David Piacquad(Executive Officer)Brian M. McNamee(Executive Officer)inRobert A. Bradway(Executive Officer, Director)David J. Scott(Executive Officer)
Co-investorsAsset Management CompanyBOMBoulder VenturesMayfield FundSunstone Capital
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge, GB
Gregory Winter(Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalDementia Discovery FundLongwood FundSR One Capital Management+4 more
Corcept develops cortisol modulators — molecules that regulate cortisol activity at the glucocorticoid receptor — to treat serious diseases across endocrinology, oncology, metabolism, and neurology.
AI & Machine LearningBiotechHealthtechMedical Devices
Joseph K. Belanoff(Chief Executive Officer and President)
Co-investorsLongitude CapitalMountain Group Capital
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management Company+14 more
Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
BiotechDigital HealthHealthtechMedical Devices
Will Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSara Bonstein(Chief Financial Officer)inRoger Adsett(Chief Operating Officer)Martina Flammer(Chief Medical Officer)inS. Nicole Schaeffer(Chief People Strategy Officer)in
Co-investorsBessemer Venture PartnersF-Prime CapitalForesite CapitalHercules Capital, Inc.OrbiMedProspect Venture Partners+1 more
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Co-investorsage1Atlas VentureAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalOrbiMed+2 more
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients.
BiotechHealthtechMedical Devices
Scott Koenig(Director)inEric Risser(President and Chief Executive Officer)in
Co-investorsHavencrest Capital ManagementRiverVest Venture PartnersSaints CapitalSanofi VenturesLa CaisseTPG
miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.
BiotechBoulder, US
William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in
Co-investorsBrace PharmaBroadview VenturesMC Healthcare VenturesAtlas VentureBoulder VenturesHeartland+1 more
Peloton develops connected fitness equipment and a digital fitness app that delivers personalized workout classes and training guidance to home exercisers.
ConsumerHardwareWellness & FitnessNew York, US
Graham Stanton(Founder)John Foley(Founder)inHisao Kushi(Founder)inPeter Stern(Chief Executive Officer and President)inElizabeth Coddington(Chief Financial Officer)Nick Caldwell(Chief Product Officer)in
Co-investorsAnsa CapitalBlue CollectiveBullishCade VenturesCoatue ManagementFELIX CAPITAL+22 more
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
BoardROBERT ADELMAN(Director)
Co-investorsage1Agent CapitalAliment CapitalBrace PharmaF-Prime CapitalOCV Partners+6 more
Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.
BiotechDeep TechMedical DevicesSouth San Francisco, US
Tim Lu(Co-Founder and Chief Executive Officer)inPhilip Lee(Executive Officer)inKanya Rajangam(President, Head of Research & Development and Chief Medical Officer)inYvonne Li(Executive Officer)inJames Collins(Director)Timothy Lu(Founder)
Co-investorsEvolution VC PartnersFlucas VenturesGreen Sands EquityLifeforce CapitalLifeSci Venture PartnersLux Capital+13 more
Sutro is a biotech company developing a cell-free protein synthesis platform for the design and manufacturing of complex biologics, particularly cancer therapies and antibody-drug conjugates.
BiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
William J. Newell(Executive Officer, Director)Jane Chung(Chief Executive Officer)inHans-Peter Gerber(Chief Scientific Officer)inDavid Pauling(Chief Administrative Officer and General Counsel)inJonathan Fawcett(VP, Head of Clinical Development)inDevendra Luhar(SVP, Technical Operations)in
Co-investorsOwl CapitalSamsara BioCapitalSolasta VenturesSV Health InvestorsVida Ventures
Jean-Paul Clozel(Founder)
Co-investorsSofinnova VenturesJohnson & Johnson Innovation – JJDC
A biopharmaceutical company with over 30 years of experience developing and commercializing treatments for central nervous system (CNS) diseases.
BiotechHealthtech
Co-investorsBioBritDag Ventures
Boulder-based biopharmaceutical company developing targeted small molecule cancer drugs; acquired by Pfizer in 2019.
Co-investorsARCH Venture PartnersFrazier Life SciencesBoulder Ventures
Arrowhead Pharmaceuticals develops RNAi-based therapeutics using its targeted RNAi molecule (TRiM) platform, which silences disease-causing genes for conditions with significant unmet medical needs.
Biotech
BioMarin is a biotechnology company that develops medicines derived from genetic discoveries to treat serious and rare diseases.
BiotechHealthtech
Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.
BiotechHealthtechCambridge, US
Nick Lydon(Director)Christoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in
BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)
Co-investorsF-Prime CapitalForesite CapitalNextech InvestRA CapitalWellington ManagementThird Rock Ventures
Developed targeted cancer therapies with companion diagnostics (Rubraca); IPO'd in 2011 (NASDAQ: CLVS).
Patrick Mahaffy(Founder)in
Co-investorsAisling CapitalFrazier Life SciencesNew Enterprise Associates (NEA)Pfizer Venture Investments
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalLumira Ventures+5 more
A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.
BiotechDigital HealthHealthtech
Co-investorsAccess BiotechnologyBain Capital Life SciencesOxford Bioscience PartnersRA Capital
Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions.
BiotechHealthtechSan Francisco, US
Thomas B. Neff(Executive Officer, Director)Frank H. Valone(Executive Officer)inK. Peony Yu(Executive Officer)inPat Cotroneo(Executive Officer)inRory Riggs(Founder)
BoardRory B. Riggs(Director)
Co-investorsAvalon BioVenturesForesite CapitalScientia VenturesMaverick Ventures
Foundation Medicine is a precision medicine company that develops comprehensive genomic profiling and companion diagnostic tests for cancer and other diseases.
BiotechDigital HealthMedical DevicesBoston, US
Alexis Borisy(Founder)Eric Lander(Founder)Levi Garraway(Founder)Todd Golub(Founder)
Co-investorsGV (Google Ventures)Khosla VenturesKleiner PerkinsNSG VenturesAndreessen HorowitzCasdin Capital+1 more
Global Blood Therapeutics was a South San Francisco biopharmaceutical company founded in 2011 focused on treatments for sickle cell disease.
South San Francisco, US
John Schembri(Executive Officer)inTed W. Love(Executive Officer, Director)in
BoardKevin Starr(Director)inCharles Homcy, M.D.(Director)
Co-investorsAisling CapitalAvoro Capital AdvisorsRA CapitalThird Rock VenturesWellington Management
GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with an R&D pipeline of eight programs focused on acute-on-chronic liver failure, hepatic encephalopathy, cholangiocarcinoma, and urea cycle disorders/organic acidemias.
BiotechHealthtech
Co-investorsredalpine
A research-intensive biopharmaceutical company that develops medicines and vaccines.
BiotechHealthtechSouth San Francisco, US
Luke Nathaniel Walker(Executive Officer)Julie Eastland(Executive Officer, Director)in
BoardRonald Hunt(Director)Mark Chin(Director)Alan Colowick(Director)Jonathan Drachman(Director)
Co-investorsK2 HealthVenturesTaiho Ventures, LLCArix BioscienceLilly Asia VenturesMPM BioImpactNew Leaf Venture Partners+1 more
Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.
BiotechHealthtechBurlingame, US
Daniel J. Capon(Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)inHarold E. "Barry" Selick(Chief Executive Officer & Director)Paul Brunetta(Chief Medical Officer)in
Co-investorsPoint72Agent CapitalBaruch Future VenturesInVivium Capital
Immutep is a late clinical-stage biotechnology company developing immunotherapies targeting the LAG-3 (Lymphocyte Activation Gene-3) immune molecule to treat cancer and autoimmune diseases.
BiotechHealthtech
Incyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas.
BiotechHealthtechMedical DevicesWilmington, US
Bill Meury(Chief Executive Officer)inPablo J. Cagnoni(President, Incyte and Global Head of R&D)in
Co-investorsDecheng Capital
Intellia is a consulting firm that helps public sector organizations transform their services by integrating digital solutions, reducing costs, and managing workforce transitions.
GovTech
Co-investorsFatima Gobi VenturesGobi PartnersOrbiMed
Intercept Pharmaceuticals develops and commercializes treatments for rare and serious liver and other diseases, with a focus on conditions such as primary biliary cholangitis.
BiotechHealthtechMedical Devices
Co-investorsAisling CapitalBioBritSamsara BioCapital
InterMune was a Brisbane, California biotechnology company focused on pulmonology and fibrotic diseases, best known for developing pirfenidone (Esbriet) to treat idiopathic pulmonary fibrosis.
daniel welchinScott Harkonen(Founder)
Co-investorsSanderling VenturesSofinnova VenturesNew Enterprise Associates (NEA)
Ionis Pharmaceuticals is a biopharmaceutical company that discovers and develops RNA- and DNA-targeted medicines using its antisense chemistry platform for people with serious diseases.
BiotechCarlsbad, US
Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.
BiotechDigital HealthHealthtechCambridge, US
PETER M. HECHT(Executive Officer, Director)inMARK G. CURRIE(Executive Officer)inHALLEY E. GIBLERT(Executive Officer)THOMAS GRANEY(Executive Officer)THOMAS A. MCCOURT(Executive Officer)in
BoardTERRANCE G. MCGUIRE(Director)
Co-investorsF-Prime CapitalMountain Group CapitalVenrockMaverick VenturesPolaris Partners
Seattle-based cancer immunotherapy company developing CAR-T and TCR cell therapies; acquired by Celgene, now part of Bristol-Myers Squibb.
BiotechSeattle, US
Hans Bishop(Executive Officer, Director, Promoter)Richard Klausner(Director, Promoter)Bernard J. Cassidy(Executive Officer)Robert Azelby(Executive Officer)Sunil Agarwal(Executive Officer)Rupert Vessey(Director)
Co-investorsARCH Venture PartnersBezos ExpeditionsAlaska Permanent Fund CorporationCrestline InvestorsVenrock
Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).
BiotechHealthtechCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)
Co-investorsBain Capital Life SciencesF-Prime CapitalLightstone VenturesNew Enterprise Associates (NEA)Nextech InvestPfizer Venture Investments+3 more
BiotechHealthtech
Jean-Paul Kress, M.D.in
Co-investorsAtlas VentureBayern Kapital
Eledon develops tegoprubart, an anti-CD40L antibody immunosuppressant for organ transplant recipients, aimed at preventing transplant rejection and extending organ longevity.
BiotechLongevityMedical Devices
Steven Perrin(President and Chief Scientific Officer)
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Co-investorsCurative VenturesForesite CapitalNextech InvestThe Column GroupVida Ventures
Bob Dugganin
Co-investorsAsset Management CompanyKleiner PerkinsVenrock
BiotechBoston, US
Darlene Deptula-Hicks(Executive Officer)inStephen S. Yoder(Executive Officer, Director)inDarlene M. Deptula-Hicks(Acting Chief Financial Officer)in
BoardChau Khuong(Director)inChristina Takke(Director)Steven Prelack(Director)
Co-investorsBiotechnology Value FundFrazier Life SciencesOrbiMed
San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.
BiotechSan Diego, US
Marcus Boehm(Executive Officer)inRobert Peach(Executive Officer)inRaymond Stevens(Director)inFaheem Hasnain(Executive Officer, Director)inJames Schmidt(Executive Officer)inChrysa Mineo(Executive Officer)in
Co-investorsARCH Venture PartnersOUP (Osage University Partners)VenrockLilly Ventures
Regeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease.
BiotechHealthtechTarrytown, US
Co-investorsSanderling VenturesvenBio PartnersWireframe Ventures
Reverie Labs develops cancer treatments designed to cross the blood-brain barrier and treat tumors in the central nervous system.
AI & Machine LearningBiotechHealthtechBoston, US
Ankit Gupta(Founder)inConnor Duffy(Founder)inJonah Kallenbach(Founder)in
Co-investorsDorm RoomLifeforce CapitalRuvento Ventures Pte Ltd.UNCOMMON DENOMINATORWireframe VenturesWormhole Capital+16 more
Sangamo Therapeutics develops gene-editing therapeutics using zinc finger and modular integrase platforms to treat genetic diseases including hemophilia, Fabry disease, and neuropathy.
BiotechDeep TechHealthtechMedical DevicesUnknown based on the provided page content, US
Sandy Macrae(Chief Executive Officer)in
Co-investorsCalifornia Technology VenturesFoothill VenturesForesite Capital
Scout is an AI-native reporting and analytics platform designed for CPG (consumer packaged goods) sales teams, automating the conversion of POS and syndicated data into dashboards, reports, and narratives for retail negotiations.
AI & Machine LearningConsumerData & InfrastructureEnterprise SoftwareRetail TechSaaSSan Francisco, US
Sasha Zhang(Founder)in
Co-investorsHolland CapitalThe E14 FundY CombinatorAlign VenturesBooz Allen VenturesDecisive Point+3 more
SeaGen develops automated robots that monitor aquatic ecosystems and remove pollutants while supporting the growth of beneficial species like seaweed to improve food and water security and reduce atmospheric carbon.
CleantechClimate TechRobotics
Co-investorsAera VCAlly Bridge GroupRA CapitalT. Rowe Price
BiotechHealthtechMedical DevicesNew York, US
Charles Pfizer
Co-investorsSofinnova Ventures
GSK is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients.
BiotechHealthtechLondon, GB
Mary Lynne Hedley(Executive Officer, Director)Leon O. Moulder, Jr.(Executive Officer, Director)Jeffrey Hanke(Executive Officer)Joseph L. Farmer(Executive Officer)inGrant C. Bogle(Executive Officer)Martin H. Huber(Executive Officer)
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Pappas CapitalAvoro Capital Advisors
uniQure is a biotech company developing gene therapies for serious genetic diseases.
BiotechHealthtechMedical Devices
Co-investorsAdvent Life SciencesALS Investment FundForesite CapitalHEALTHCARE ROYALTY PARTNERSForbion
Vertex provides a governance-preserving 3D access layer that streams context-aware pixels from product lifecycle management (PLM) systems to manufacturing, suppliers, and operations teams without exporting derivative geometry files.
Advanced ManufacturingEnterprise Software
Co-investorsNext Level VenturesSBI JI Innovation Advisory Ltd.Hyde Park Angels
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Acorda TherapeuticsAdams Respiratory TherapeuticsAlder BiopharmaceuticalsALDRAlnylamAriadAriad PharmaceuticalsARMO BioSciencesArobioArquleArvinasBiogenBMRNButterfly NetworkCara TherapeuticsCelatorCelator PharmaceuticalsCelgeneCogent BiosciencesCoLucidCoriumDicernaEledon PharmaceuticalsEpizymeExonics TherapeuticsF StarFive PrimeFive Prime TherapeuticsGenfitGenzyme CorporationIgnytaInfinity PharmaceuticalsIonis PharmaceuticalsIronwoodKarus TherapeuticsKaryopharmMersanaMomentaMomenta PharmaceuticalsOnyx PharmaceuticalsOSI PharmaceuticalsPacira BioSciencesPacira PharmaceuticalsPharmassetPharmionPierisReata PharmaceuticalsRegeneronSangamoThe Medicines CompanyTSROUCBUnited TherapeuticsUTHRVertex PharmaceuticalsViracta Therapeutics
Exits · 30
14 IPOs · 16 acquisitions · showing 264D Molecular TherapeuticsNASDAQ: FDMTAdaptimmuneOTC: ADAPYAmgenNASDAQ: AMGNBicycleNASDAQ: BCYCCorcept TherapeuticsNASDAQ: CORTFreenomeNASDAQ: FRNMInsmedNASDAQ: INSMIntellia TherapeuticsNASDAQ: NTLAMacrogenics IncNASDAQ: MGNXmiRagen TherapeuticsNASDAQ: VRDNPelotonNASDAQ: PTONPrecision BioSciencesNASDAQ: DTILSenti BiosciencesNASDAQ: SNTISutrobioNASDAQ: STROAdamaspharmaacq. by Supernus PharmaceuticalsCoLucidacq. by LillyDicernaacq. by Novo NordiskFive Prime Therapeuticsacq. by AmgenGlobal Blood Therapeuticsacq. by PfizerIntercept Pharmaceuticalsacq. by AlfasigmaInterMuneacq. by RocheMorphoSysacq. by NovartisPeloton Therapeuticsacq. by MerckReata Pharmaceuticalsacq. by BiogenSeattle Geneticsacq. by PfizerThe Medicines Companyacq. by Novartis
Portfolio news
latest coverage across their companiesIronwood Pharmaceuticals · finance.yahoo.com · Aug 6, 2026
Blueprint Medicines · trysignalbase.com · Mar 25, 2026
Frequently asked questions
- How many investments has Ridgeback Capital made?
- Ridgeback Capital has 111 tracked investments, 30 of which have exited, including 1 dated in the last 24 months.
- What stage does Ridgeback Capital invest at?
- Ridgeback Capital invests at the Seed, Late Stage stages.
- What sectors does Ridgeback Capital focus on?
- Ridgeback Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Ridgeback Capital located?
- Ridgeback Capital is headquartered in New York, US.
- Who does Ridgeback Capital co-invest with?
- Ridgeback Capital most often shares deals with Kleiner Perkins, Foresite Capital, New Enterprise Associates (NEA), among 147 tracked co-investors.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.